HR 4388, the PREP Repeal Act, removes legal immunity for pharmaceutical companies that developed or distributed pandemic-related products (like vaccines or treatments) during public health emergencies. It repeals key sections of the PREP Act that previously shielded manufacturers from lawsuits over injuries or harm caused by these products. The bill ensures people can still pursue civil lawsuits under existing federal or state law for harm from drugs, devices, biological products, or pandemic countermeasures. This change applies only to cases pending or filed after the law's enactment, preserving current legal rights while ending the broad liability protection.
HR 4744 establishes a federal grant program to fund community-based mental wellness and resilience initiatives. It provides planning grants (up to $250,000) and program grants (up to $500,000 annually for four years) to local coalitions - groups formed by representatives from at least five community sectors like schools, health services, faith organizations, and businesses. These coalitions must use a public health approach to identify community strengths and risks, build social connections, and implement evidence-based programs addressing mental wellness for all ages. The bill authorizes $36 million over five years (2025-2029), with 20% reserved for rural areas, and requires grantees to develop strategic plans and report on outcomes by 2030.
S 783, the Assistance for Rural Water Systems Act of 2025, provides new financial assistance to rural water, wastewater, and waste disposal systems. It authorizes grants, zero-percent or 1% interest loans, and loan modifications/forgiveness for eligible entities facing public health risks or financial hardship in economically distressed areas. The bill requires the Secretary to establish affordability metrics (cost per household as a percentage of median income) to determine eligibility for assistance targeting distressed communities. This directly affects rural water systems in disadvantaged areas by offering flexible financial support to maintain essential services. The legislation focuses on concrete policy changes to improve water system sustainability without speculative outcomes.
This bill reauthorizes funding for the Healthy Start Initiative, which provides maternal and infant health services to at-risk communities. It specifies $145 million annually for fiscal years 2026 through 2030 to support existing Healthy Start programs. The bill modifies the funding language in the Public Health Service Act to continue these services without changing program requirements. It directly affects local health organizations operating under the Healthy Start Initiative.
S 473, the SENIOR Act, requires the federal government to assess loneliness among older adults as part of existing aging programs. It amends the Older Americans Act to explicitly include "loneliness" alongside "social isolation" in program definitions and mandates a report on how current programs address loneliness's health impacts. The report must analyze loneliness prevalence, health effects, program effectiveness, and the role of family connections across generations, with an interim report due in 2 years and a final report in 5 years. This bill directly affects older individuals identified as having "greatest social need" through programs funded by the Administration on Aging. The legislation focuses on data collection and evaluation, not new funding or immediate policy changes.
HR 1432, the LIABLE Act, removes federal immunity for manufacturers of authorized COVID-19 vaccines regarding claims of injury or loss from vaccine administration or use. It directly affects vaccine manufacturers by allowing individuals to pursue civil lawsuits for vaccine-related harm, regardless of prior compensation through existing programs like the National Vaccine Injury Compensation Program. The bill explicitly overrides previous laws (such as sections 319F-3, 2111, and 2122 of the Public Health Service Act) that previously limited manufacturer liability. This law applies retroactively to all vaccine administration or use occurring before, during, or after the bill’s enactment.
This bill clarifies that equipment designed to detect fentanyl or xylazine in substances is exempt from certain restrictions under the Controlled Substances Act. It amends Section 422 to explicitly state that possessing, selling, or transporting such testing equipment does not violate federal law. The change directly affects harm reduction organizations, first responders, and public health groups using these tools to identify dangerous substances and prevent overdoses.
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
This bill reauthorizes the Young Women’s Breast Health Education and Awareness program through 2031, extending its authorization period by five years (from 2026 to 2031). It directly affects the existing program established under the 2009 law, which provides funding for breast health education and awareness initiatives targeting young women. The key provision is a simple date amendment in the Public Health Service Act to update the program’s expiration date. As a procedural reauthorization, it does not create new policies or alter program requirements.
HR 2715, the *Destruction of Hazardous Imports Act*, expands the authority to destroy imported goods that pose public health risks. It amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to order the destruction of any refused import (not just drugs or devices) if it presents a significant health concern. The bill also prohibits the unauthorized movement, sale, or export of such refused goods. These changes apply to importers of hazardous refused articles 180 days after enactment, with the FDA required to finalize implementing regulations within 90 days.
